[1]张燕,贾维军,张瑞,等.多发性骨髓瘤患者骨髓骨硬化蛋白和核因子-κB受体活化因子表达及临床意义[J].中国中医骨伤科杂志,2024,32(04):44-48+54.[doi:10.20085/j.cnki.issn1005-0205.240409]
　ZHANG Yan,JIA Weijun,ZHANG Rui,et al.Expression and Clinical Significance of Sclerostin and RANKL in Multiple Myeloma Patients[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2024,32(04):44-48+54.[doi:10.20085/j.cnki.issn1005-0205.240409]
点击复制

多发性骨髓瘤患者骨髓骨硬化蛋白和核因子-κB受体活化因子表达及临床意义()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第32卷
期数:
2024年04期
页码:
44-48+54
栏目:
临床研究
出版日期:
2024-04-01

文章信息/Info

Title:
Expression and Clinical Significance of Sclerostin and RANKL in Multiple Myeloma Patients
文章编号:
1005-0205(2024)04-0044-05
作者:
张燕1; 贾维军1; 张瑞1; 许加华1
1巴中市中心医院(四川 巴中,636000)
Author(s):
ZHANG Yan1; JIA Weijun1; ZHANG Rui1; XU Jiahua1
1Bazhong Central Hospital,Bazhong 636000,Sichuan China.
关键词:
多发性骨髓瘤;  骨硬化蛋白;  核因子-κB受体活化因子;  临床病理特征
Keywords:
multiple myeloma;  sclerostin;  receptor activator of NF-κB ligand;  clinicopathological features
分类号:
R73.81
DOI:
10.20085/j.cnki.issn1005-0205.240409
文献标志码:
A
摘要:
目的:探讨多发性骨髓瘤(MM)患者骨髓上清液中骨硬化蛋白(Sclerostin)和核因子-κB受体活化因子(RANKL)表达水平及其临床意义。方法:收集2018年1月至2020年6月就诊的60例多发性骨髓瘤患者作为研究对象,基于国际分期系统(ISS)分期将多发性骨髓瘤患者分为ISS Ⅰ期、Ⅱ期和Ⅲ期,其中ISS Ⅰ期患者18例,ISS Ⅱ期患者23例,ISS Ⅲ期患者19例。同时将同期通过骨髓穿刺证明其骨髓功能正常且无血液系统病症的58例健康人群作为对照组。收集整理多发性骨髓瘤患者的年龄、性别、体重指数、校正血钙、骨损伤、C反应蛋白和乳酸脱氢酶等临床病理资料,检测并对比多发性骨髓瘤组和对照组骨髓骨硬化蛋白及RANKL表达水平。分析不同ISS分期的多发性骨髓瘤患者骨髓骨硬化蛋白和RANKL表达水平; 采用Pearson等级相关分析多发性骨髓瘤患者骨髓骨硬化蛋白和RANKL表达水平相关性; 采用Kaplan-Meier法分析骨髓骨硬化蛋白和RANKL表达水平与多发性骨髓瘤患者3年生存率的关系。结果:与对照组相比,多发性骨髓瘤组骨髓骨硬化蛋白和RANKL表达水平均显著升高(P<0.05)。多发性骨髓瘤患者临床病理特征结果显示,患者骨髓骨硬化蛋白和RANKL表达水平与校正血钙、C反应蛋白和乳酸脱氢酶等密切相关(P<0.05)。不同ISS分期的多发性骨髓瘤患者骨髓骨硬化蛋白和RANKL表达水平差异有统计学意义(P<0.05),与ISS Ⅰ期和Ⅱ期患者相比,ISS Ⅲ期患者骨髓骨硬化蛋白和RANKL表达水平显著升高(P<0.05),ISS Ⅱ期患者骨髓骨硬化蛋白和RANKL表达水平显著高于ISS Ⅰ期多发性骨髓瘤患者(P<0.05)。Pearson等级相关分析显示,多发性骨髓瘤患者骨髓骨硬化蛋白和RANKL表达水平正相关(r=0.551,P<0.001)。Kaplan-Meier结果显示骨髓骨硬化蛋白高表达者的3年生存率低于骨硬化蛋白低表达者(χ2=3.916,P<0.05),骨髓RANKL高表达的多发性骨髓瘤患者3年生存率低于RANKL低表达患者(χ2=4.223,P<0.05)。结论:多发性骨髓瘤患者骨髓骨硬化蛋白和RANKL表达水平显著升高,且二者对于预测多发性骨髓瘤患者预后具有重要的临床应用价值。
Abstract:
Objective:To investigate the expression levels of sclerostin and receptor activator of NF-κB ligand(RANKL)in bone marrow supernatant of multiple myeloma(MM)patients and their clinical significance.Methods:60 patients with MM from January 2018 to June 2020 were collected as research objects.Based on the International Staging System(ISS),patients with MM were divided into ISS stage Ⅰ,Ⅱ and Ⅲ stages,including 18 patients with ISS stage Ⅰ,23 patients with ISS stage Ⅱ and 19 patients with ISS stage Ⅲ.At the same time,58 patients who proved that their bone marrow function was normal through bone marrow aspiration and non-hematological diseases were included as the control group.The clinicopathological data of MM patients including age,sex,body mass index(BMI),corrected blood calcium,bone injury,C-reactive protein and lactate dehydrogenase were collected and sorted.The expression levels of sclerostin and RANKL in bone marrow of MM group and control group were detected and compared.The expression levels of sclerostin and RANKL in bone marrow of MM patients with different ISS stages were analyzed.The correlation between the expression levels of RANKL and sclerostin in bone marrow of MM patients was analyzed by Pearson grade correlation.Kaplan-Meier method was used to analyze the relationship between the expression levels of sclerostin and RANKL in bone marrow and the three-year survival rate of MM patients.Results:Compared with control group,the expression levels of sclerostin and RANKL in bone marrow of MM group were significantly increased(P<0.05).The clinicopathological characteristics of MM patients showed that the expression levels of sclerostin and RANKL in bone marrow were closely correlated with corrected blood calcium,C-reactive protein and lactate dehydrogenase(P<0.05).There were significant differences in the expression levels of bone marrow sclerostin and RANKL in MM patients with different ISS stages(P<0.05).Compared with patients with ISS stage Ⅰ and Ⅱ,the expression levels of bone marrow sclerostin and RANKL were significantly increased in patients with ISS stage Ⅲ(P<0.05).The expression levels of sclerostin and RANKL in bone marrow of ISS stage Ⅱ patients were significantly higher than those of ISS stage Ⅰ MM patients(P<0.05).Pearson grade correlation analysis showed that the expression levels of bone marrow sclerostin and RANKL were positively correlated in MM patients(r=0.551,P<0.001).Kaplan-Meier results showed that the 3-year survival rate of patients with high expression of sclerostin in bone marrow was lower than that of patients with low expression of RANKL(χ2=3.916,P<0.05),and the 3-year survival rate of patients with high expression of RANKL in bone marrow was lower than that of patients with low expression of RANKL(χ2=4.223,P<0.05).Conclusion:The expression levels of sclerostin and RANKL in bone marrow of MM patients were significantly increased,and both of them had important clinical application value in predicting the prognosis of MM patients.

参考文献/References:

[1] 韩东海,骈晓琴,申清云,等.TIM-3、hPEBP4在多发性骨髓瘤患者BMCS中的水平及其与体内硼替佐米累积量的相关性研究[J].国际检验医学杂志,2023,44(11):1393-1396.
[2] 张永梅,张志敏,周洁,等.LncRNA CBR3-AS1在多发性骨髓瘤中的表达及临床意义[J].基础医学与临床,2023,43(6):948-952.
[3] MUKKAMALLA S K R,MALIPEDDI D.Myeloma bone disease:a comprehensive review[J].Int J Mol Sci,2021,22(12):6208-6228.
[4] 郑兰兰,李斌.sBCMA在初诊多发性骨髓瘤患者中的表达水平及其与预后的关系[J].中国实验血液学杂志,2023,31(4):1108-1112.
[5] DELGADO-CALLE J,SATO A Y,BELLIDO T.Role and mechanism of action of sclerostin in bone[J].Bone,2017,96(1):29-37.
[6] GOLLEDGE J,THANIGAIMANI S.Role of sclerostin in cardiovascular disease[J].Arterioscler Thromb Vasc Biol,2022,42(7):e187-e202.
[7] TAKAYANAGI H.RANKL as the master regulator of osteoclast differentiation[J].J Bone Miner Metab,2021,39(1):13-18.
[8] YASUDA H.Discovery of the RANKL/RANK/OPG system[J].J Bone Miner Metab,2021,39(1):2-11.
[9] 史青林,顾炎,沈旭星,等.修订的国际分期系统对初诊多发性骨髓瘤的预后意义[J].临床血液学杂志,2018,31(5):359-364.
[10] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2017年修订)[J].中华内科杂志,2017,56(11):866-870.
[11] BERGSTROM D J,KOTB R,LOUZADA M L,et al.Consensus guidelines on the diagnosis of multiple myeloma and related disorders:recommendations of the myeloma Canada research network consensus guideline consortium[J].Clin Lymphoma Myeloma Leuk,2020,20(7):e352-e367.
[12] BERNSTEIN Z S,KIM E B,RAJE N.Bone disease in multiple myeloma:biologic and clinical implications[J].Cells,2022,11(15):2308-2325.
[13] GUZDAR A,COSTELLO C.Supportive care in multiple myeloma[J].Curr Hematol Malig Rep,2020,15(2):56-61.
[14] HO M,PATEL A,GOH C Y,et al.Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance(MGUS)and smoldering multiple myeloma(SMM)[J].Leukemia,2020,34(12):3111-3125.
[15] MAES A,MENU E,VEIRMAN K,et al.The therapeutic potential of cell cycle targeting in multiple myeloma[J].Oncotarget,2017,8(52):90501-90520.
[16] PADALA S A,BARSOUK A,BARSOUK A,et al.Epidemiology,staging,and management of multiple myeloma[J].Med Sci(Basel),2021,9(1):3-16.
[17] MAEDA K,KOBAYASHI Y,KOIDE M,et al.The regulation of bone metabolism and disorders by Wnt signaling[J].Int J Mol Sci,2019,20(22):5525-5561.
[18] MARINI F,GIUSTI F,PALMINI G,et al.Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders[J].Osteoporos Int,2023,34(2):213-238.
[19] 范小红,王雪莲,孟亚红.血清MIP-1α、TRACP-5b和骨硬化蛋白水平在多发性骨髓瘤病情和预后中的临床价值[J].检验医学与临床,2023,20(2):150-154.
[20] ONO T,HAYASHI M,SASAKI F,et al.RANKL biology:bone metabolism,the immune system,and beyond[J].Inflamm Regen,2020,40:2-17.
[21] UDAGAWA N,KOIDE M,NAKAMURA M,et al.Osteoclast differentiation by RANKL and OPG signaling pathways[J].Journal of Bone and Mineral Metabolism,2020,39(1):19-26.
[22] 王君,鲍其远,彭程,等.骨恶性肿瘤RANKL表达分析及地舒单抗疗效观察[J].中国骨与关节杂志,2023,12(5):337-344.

更新日期/Last Update: 2024-04-15